Ixabepilone and other epothilones: Microtubule-targeting agents for metastatic breast cancer Journal Article
| Authors: | Morris, P. G.; Fornier, M. N. |
| Article Title: | Ixabepilone and other epothilones: Microtubule-targeting agents for metastatic breast cancer |
| Abstract: | Taxanes, derived from the bark of the Pacific yew tree, were the last major group of cytotoxic agents to be developed. Their proven efficacy in a variety of malignancies has constituted a real breakthrough in the treatment of cancer. Wider clinical use of taxanes has several important limitations, including acquired and intrinsic tumor resistance, hypersensitivity reactions, and cumulative neurotoxicity and hematopoietic toxicity. Epothilones, naturally occurring macrolide antibiotics that also act on the microtubule, are a novel class of compounds that may circumvent some of these problems. Many synthetic and semisynthetic epothilone analogs have been formulated and have undergone varying degrees of testing. These compounds have demonstrated activity in a variety of tumors, including in tumors and cell lines resistant to taxanes. So far only ixabepilone has been tested in phase II and III trials and licensed by the US Food and Drug Administration for the treatment of metastatic breast cancer. The main dose-limiting toxicity appears to be a sensory peripheral neuropathy, as commonly seen with drugs that act on the microtubule. Further clinical studies assessing the role of ixabepilone in other settings, as well as the clinical investigation of other epothilones, are eagerly awaited. |
| Keywords: | cancer chemotherapy; unclassified drug; clinical trial; fatigue; neutropenia; bevacizumab; cytotoxic agent; doxorubicin; diarrhea; drug efficacy; nonhuman; side effect; antineoplastic agents; clinical trials as topic; drug approval; united states; drug targeting; capecitabine; paclitaxel; neurotoxicity; antineoplastic agent; anorexia; carboplatin; metastasis; multiple cycle treatment; ovary cancer; sensory neuropathy; breast cancer; bone marrow suppression; blood toxicity; lung non small cell cancer; neuropathy; vomiting; myalgia; peripheral neuropathy; antineoplastic activity; food and drug administration; drug design; breast neoplasms; cetuximab; febrile neutropenia; head and neck cancer; breast tumor; neoplasm metastasis; drug derivative; nail; stomach cancer; taxane derivative; trastuzumab; hand foot syndrome; metastatic breast cancer; microtubule; macrolide; lapatinib; hypersensitivity reaction; tumor resistance; drug use; imidazoles; ixabepilone; sagopilone; epothilones; taxanes; 21 aminoepothilone b; 9,10 didehydroepothilone d; abj 879; epothilone a; epothilone b; epothilone d; epothilone derivative; kos 682; imidazole derivative; n(delta) (5 methyl 4 oxo 2 imidazolin 2 yl)ornithine; n(delta)-(5-methyl-4-oxo-2-imidazolin-2-yl)ornithine; ornithine; tubulin modulator; tubulin modulators |
| Journal Title: | Clinical Advances in Hematology & Oncology |
| Volume: | 7 |
| Issue: | 2 |
| ISSN: | 1543-0790 |
| Publisher: | Millennium Medical Publishing, Inc |
| Date Published: | 2009-02-01 |
| Start Page: | 115 |
| End Page: | 122 |
| Language: | English |
| PUBMED: | 19367253 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "Source: Scopus" |
Citation Impact
Related MSK Work